Explore our corporate updates and press releases below. For the latest news, follow us on LinkedIn.
To learn more about our company, visit our Corporate Overview page. To see our progress toward new answers and disease-centric therapies, visit our Pipeline page or review recent articles and studies on our Publications page.
|11/09/2023||November 2023 Update||Corporate Update|
|11/09/2023||Ichnos Sciences Data Selected For Presentation at the 65th ASH Annual Meeting||Press Release|
|11/02/2023||Ichnos Sciences Announces Initiation of First-In-Human Clinical Trial for ISB 2001||Press Release|
|10/11/2023||Ichnos Sciences Enters Licensing Agreement For OX40 Antagonist Monoclonal Antibody Portfolio With Astria Therapeutics||Press Release|
|10/03/2023||Ichnos Sciences Promotes Dean Thomas To General Counsel||Press Release|
|08/10/2023||August 2023 Update||Corporate Update|
|07/07/2023||Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Trispecific Antibody, ISB 2001||Press Release|
|06/23/2023||Ichnos Sciences Welcomes Lida Pacaud, M.D., as New Chief Medical Officer||Press Release|
|05/18/2023||May 2023 Update||Corporate Update|
|03/20/2023||Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) Antibody Innate Cell Modulator, ISB 1442||Press Release|
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.